Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phenotypic and Site Directed Mutagenesis Analysis on the Impact of V106I in HIV-1 Reverse Transcriptase on Resistance to Doravirine

NCT04894357 is registered in ClinicalTrials.gov with Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental as lead sponsor.

NCT NCT04894357
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04894357 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phenotypic and Site Directed Mutagenesis Analysis on the Impact of V106I in HIV-1 Reverse Transcriptase on Resistance to Doravirine
Lead sponsor
Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental
Phase
Observational
Overall status
Unknown status
Start date
September 1, 2021
Completion date
May 1, 2022
Enrollment
50 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hiv-1-infection